The Glaucoma Research Foundation
San Francisco – November 4, 2009 – The Glaucoma Research Foundation announced today that Adrienne L. Graves, PhD has been appointed to its Board of Directors. Dr. Graves is President and CEO of Santen Inc., a wholly owned subsidiary of Japan’s Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4536).
Kuldev Singh, MD, MPH, Board Chair of the Glaucoma Research Foundation and Director of Glaucoma Service and Professor of Ophthalmology at Stanford University, commented, “Having observed the quality of Dr. Graves’ work as a scientist and CEO, I feel she brings tremendous energy, experience and qualifications to the board.”
Thomas M. Brunner, President and CEO of the Glaucoma Research Foundation, added, “The addition of Adrienne Graves will bring a desired and positive skill set and dynamic to our board. We’re proud to have her join what is already a varied and high quality group of medical specialists and professionals.”
Dr. Graves was trained as a visual scientist before beginning her career in the ophthalmic pharmaceutical industry. She studied visual psychophysics and electrophysiology at Brown University, University of Michigan, and University of Paris before joining Alcon Labs. Dr Graves spent 9 years at Alcon before joining Santen in 1995 to help found their U.S. operations.
In addition to her role as President and CEO of Santen Incorporated, she serves as a corporate officer for Santen Pharmaceutical Co., Ltd., and serves on the board of directors for TearLab Corporation. She also serves on the boards of the AAO (American Academy of Ophthalmology) Foundation, the Pan-American Ophthalmological Foundation, and the Corporation Committee for the Brown University Medical School. She co-founded OWL (Ophthalmic Women Leaders) with Dr. Marguerite McDonald.
About the Glaucoma Research Foundation
Founded in 1978, the mission of the Glaucoma Research Foundation is to prevent vision loss from glaucoma through investment in innovative research, education, and patient support – all directed toward the ultimate goal of finding a cure. In the three decades that have followed, more than $45 million of grants and projects have been funded by GRF. In addition to attracting innovative scientists, doctors and ideas to the field of glaucoma research, GRF also provides education and support for those with glaucoma, as well as to their families and friends.
About Santen Inc.
Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a billion-dollar global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly owned Napa, California-based Santen Inc. A detailed listing of products, as well as additional corporate information, is available online at www.santeninc.com.
# # #